Overview: Pfizer stock is trading near $25.86 with moderate upside potential based on the forecast range of up to ...

New York-based Pfizer Inc. (PFE) is a leading global biopharmaceutical company. With a market cap of $139.3 billion, it is ...

Pfizer has fallen behind the pack when it comes to GLP-1 drugs, but the company is still fighting.

If you are wondering whether Pfizer's current share price reflects its underlying value, you are not alone. This article will ...

Pfizer Inc. (PFE) shares are trading higher on Tuesday, as the stock benefits from a price target increase at Cantor ...

Analysts expect the New York-based company to report quarterly earnings at 57 cents per share, down from 63 cents per share ...

Pfizer may look cheap with a ~7% yield, but tight free cash flow, patent cliffs, and limited growth raise downside risk. Read ...

The healthcare giant has had trouble winning over investors in the past year despite an incredibly low valuation.

In the last six months Pfizer’s stock (NYSE: PFE) has underperformed Merck (NYSE: MRK) and J&J (NYSE: JNJ) primarily due to ...

Pfizer's stock has started to turn higher, but it is still down massively; is now the time to jump aboard?

Pfizer PFE is set to report its fourth-quarter and full-year 2025 earnings on Feb. 3, before market open. The Zacks Consensus Estimate for sales and earnings for the fourth quarter is pegged at $16.93 ...